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Abstract
Monimax® is considered safe for turkeys for fattening at the highest use level of 50 mg monensin
sodium and 50 mg nicarbazin/kg complete feed. The margin of safety is about 1.5. The simultaneous
use of Monimax® and certain antibiotic drugs (i.e. tiamulin) is contraindicated. Nicarbazin (equimolar
complex of dinitrocarbanilide (DNC) and 2-hydroxy-4,6-dimethylpyrimidine (HDP)) has no antimicrobial
activity. For both compounds of Monimax®, the metabolic pathways in the chicken are similar to those
in the turkey and rat. Monimax® does not represent a genotoxic risk. No safety concerns would arise
from the nicarbazin impurities p-nitroaniline and methyl(4-nitrophenyl) carbamate. The lowest no
observed effect level (NOEL) identiﬁed for monensin sodium in a developmental study in rabbits was
0.3 mg monensin sodium/kg body weight (bw) per day for maternal toxicity in rabbits. The lowest no
observed adverse effect level (NOAEL) identiﬁed in a 52-week study in rat using DNC + HDP was
20 mg DNC + 8 mg HDP/kg bw per day. No signiﬁcant interaction between monensin sodium and
nicarbazin is expected from toxicological studies. The use of Monimax® at the highest proposed dose
will not pose a risk to persons consuming animal products from treated turkeys for fattening. No
withdrawal time is required for Monimax® in turkeys for fattening. Residue data comply with the
established maximum residue limits (MRLs) for monensin and DNC. Monensin sodium presents a
hazard by inhalation and may also be associated with dermal toxicity. Monimax® is not a skin irritant;
however, no data are available for the eye irritation potential of monensin. Monimax® is not a skin
sensitiser. Based on the available data, the FEEDAP Panel cannot conclude on the safety of Monimax®
for the environment. Monimax® has the potential to control coccidiosis in turkeys for fattening at a
minimum concentration of 40 mg monensin sodium and 40 mg nicarbazin/kg complete feed.
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Summary
Following a request from European Commission, the Panel on Additives and Products or Substances
used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and efﬁcacy of
Monimax® (monensin sodium and nicarbazin), when used as a feed additive for turkeys for fattening.
Monimax® is considered safe for turkeys for fattening at the highest use level of 50 mg monensin
sodium and 50 mg nicarbazin/kg complete feed. The margin of safety is about 1.5. The simultaneous
use of Monimax® and certain antibiotic drugs (i.e. tiamulin) is contraindicated. Monensin has a
selective antimicrobial activity against Gram-positive bacterial species while many Enterobacteriaceae
are naturally resistant. Induction of cross-resistance with clinically relevant antimicrobials or increased
shedding of enteropathogenic bacteria are not reported. Nicarbazin has no antimicrobial activity.
Monensin sodium is absorbed at a limited extent and excreted rapidly, it is extensively metabolised
and gives rise to demethylated, oxidised and decarboxylated metabolites. Nicarbazin, when ingested, is
rapidly split in its two components 2-hydroxy-4,6-dimethylpyrimidine (HDP) and dinitrocarbanilide
(DNC) which behave independently. Liver is the target tissue. DNC residues decline rapidly from tissues
following nicarbazin withdrawal. DNC appears as the marker residue. HDP-related residues are much
lower than those derived from DNC. For both compounds of Monimax®, the metabolic pathways in the
turkey are similar to those in the chicken and rat.
The FEEDAP Panel concludes that the active substances in Monimax®, monensin sodium and
nicarbazin, do not represent a genotoxic risk. No safety concerns would arise from the nicarbazin
impurities p-nitroaniline (PNA) and methyl(4-nitrophenyl) carbamate (M4NPC). Monensin sodium has
no structural alert for carcinogenesis. Monensin sodium is not a reproductive or developmental
toxicant. The lowest no observed effect level (NOEL) identiﬁed in the developmental study in rabbits is
0.3 mg monensin sodium/kg body weight (bw) per day for maternal toxicity in rabbits. The primary
toxicity resulting from the oral use of nicarbazin is renal toxicity. The absence of similar ﬁndings after
treatment with DNC and HDP conﬁrms that this equimolar association of compounds is better tolerated
than nicarbazin at equivalent doses. The lowest no observed adverse effect level (NOAEL) identiﬁed in
a 52-week study in rat using DNC + HDP was 20 mg DNC + 8 mg HDP/kg bw per day based on the
absence of microcrystals in urine and related microscopic renal observations. No signiﬁcant interaction
between monensin sodium and nicarbazin is expected from toxicological studies.
The use of Monimax® at the highest proposed dose (50 mg monensin sodium and 50 mg
nicarbazin/kg complete feed) will not pose a risk to persons consuming animal products from treated
turkeys for fattening. No safety concern would arise from the impurity PNA if the maximum content in
nicarbazin of 0.1% is respected. The impurity M4NPC is considered safe for the consumer provided
that a maximum concentration of 0.4% in nicarbazin is not exceeded. No withdrawal time is required
for Monimax® in turkeys for fattening. Residue data comply with the established maximum residue
limits (MRLs) for monensin and DNC.
The monensin sodium contained in Monimax® presents a hazard by inhalation. Monimax® is not a
skin irritant; however, no data are available for the eye irritation potential of monensin. Monimax® may
also act as a dermal toxicant due to its monensin component. Monimax® is not a skin sensitiser.
The use of monensin sodium from Monimax® in complete feed for turkeys for fattening does not
pose a risk for the aquatic compartment and sediment, while a risk cannot be excluded for the
terrestrial compartment. A ﬁnal conclusion on the risk resulting from the use of nicarbazin from
Monimax® cannot be made because (i) DNC reﬁned predicted environmental concentrations (PECs)
show uncertainties linked to the very high persistence of the compound, (ii) DNC might accumulate in
the sediment compartment and (iii) DNC can potentially bioaccumulate and may cause secondary
poisoning. No concerns would arise for the HDP moiety of nicarbazin excreted from chickens fed
Monimax®. Based on the available data, the FEEDAP Panel cannot conclude on the safety of
Monimax® for the environment.
The FEEDAP Panel concludes that Monimax® has the potential to control coccidiosis in turkeys for
fattening at a minimum concentration of 40 mg monensin sodium and 40 mg nicarbazin/kg complete
feed.
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